Molecular therapy for acute respiratory distress syndrome: SMAD7 inhibits acute lung injury via down regulation of its target gene, 16/April/2015, 23.10

Molecular therapy for acute respiratory distress syndrome: SMAD7 inhibits acute lung injury via down regulation of its target gene, 16/April/2015, 23.10

Molecular therapy for acute respiratory distress syndrome: SMAD7 inhibits acute lung injury via down regulation of its target gene, 16/April/2015, 23.10 150 150

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, Molecular therapy for acute respiratory distress syndrome: SMAD7 inhibits acute lung injury via down regulation of its target gene, 16/April/2015, 23.10, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Significance: This study suggests, for the first time, that SMAD7 , by suppressing the expression of its target gene, it may inhibit acute lung injury. Thereby, it may inhibit the progression of acute respiratory distress syndrome.  Thus, pharmacological formulations encompassing “SMAD7 activators  may be used to inhibit the progression of acute respiratory distress syndrome.

Amount: $ 300

Undisclosed information: How SMAD7 inhibits the progression of acute respiratory distress syndrome

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org